» Articles » PMID: 38283873

Survivorship, Complications, and Outcomes Following Distal Femoral Replacement for Neoplastic Indications

Overview
Journal J Orthop
Specialty Orthopedics
Date 2024 Jan 29
PMID 38283873
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Distal femoral replacements (DFRs) are excellent treatment options for limb salvage procedures in patients who have bone loss secondary to neoplasm. Multiple studies report adequate survivorship and complication rates following DFR implantation, primarily for non-neoplastic indications. However, current literature regarding neoplasm-specific reports is often limited by sample size, survivorship, and patient reported outcome measurements. Therefore, we sought to examine patients who received a DFR for a neoplastic indication at multiple tertiary academic centers. Specific outcomes analyzed included: (1) revision-free survival, (2) medical/surgical complications, and (3) Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR).

Methods: All patients who underwent a DFR for a neoplastic indication were retrospectively reviewed. A total of 29 knees were included for various neoplastic indications. Outcomes of interest included: post-operative thromboses, pneumonia, dislocations, periprosthetic joint infections (PJIs), aseptic loosening, osteolysis, emergency department visits, inpatient readmissions, and revision surgeries. Patient-reported outcome measure (PROM) collected included: Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR).

Results: Revision-free survivorship was 72.4 % at 23 months with radiographic follow-up. PJI was the most common post-operative complication, affecting 3 knees (10.3 %). The mean number of emergency department visits and inpatient readmissions averaged less than one per patient (0.63 and 0.41, respectively). KOOS JR scores improved markedly among from baseline to final follow-up (44.1-57.8).

Conclusion: The use of DFR led to satisfactory medium-term clinical outcomes with an acceptable complication rate for this challenging group of patients. The marked improvement in patient satisfaction for this patient population gives a promising outlook for patients who will undergo this procedure in the future and can guide patient-provider regarding surgical expectations.

References
1.
Lex J, Adlan A, Tsoi K, Evans S, Stevenson J . Frequency and reason for reoperation following non-invasive expandable endoprostheses: A systematic review. J Bone Oncol. 2021; 31:100397. PMC: 8529098. DOI: 10.1016/j.jbo.2021.100397. View

2.
ENNEKING W, Spanier S, Goodman M . A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980; (153):106-20. View

3.
Pala E, Henderson E, Calabro T, Angelini A, Abati C, Trovarelli G . Survival of current production tumor endoprostheses: complications, functional results, and a comparative statistical analysis. J Surg Oncol. 2013; 108(6):403-8. DOI: 10.1002/jso.23414. View

4.
Gusho C, Greenspoon J, Clayton B, Bauer J, Colman M, Gitelis S . Long-term outcomes and improved risk of revision following tumor endoprosthetic replacement of the distal femur: Single institutional results. J Orthop. 2021; 25:259-264. PMC: 8212066. DOI: 10.1016/j.jor.2021.05.027. View

5.
Sobol K, Fram B, Strony J, Brown S . Survivorship, complications, and outcomes following distal femoral arthroplasty for non-neoplastic indications. Bone Jt Open. 2022; 3(3):173-181. PMC: 8965790. DOI: 10.1302/2633-1462.33.BJO-2021-0202.R1. View